Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

Share Price is delayed by 15 minutes
Get Live Data
45.00    2.50 (5.88%)
Bid:
44.00
Ask:
46.00
Spread: 2.00 (4.545%)
Market Cap: £86.34m
IOF Live PriceLast checked at - London Stock Exchange

Intraday Iofina Share Chart

Board Appointment

16 Aug 2013 07:00

RNS Number : 8287L
Iofina PLC
16 August 2013
 



16 August 2013

 

Iofina plc

("Iofina" or the "Company")

(LSE AIM: IOF)

 

Board Appointment

 

Iofina, specialists in the exploration and production of iodine and iodine specialty chemical derivatives, is pleased to announce the appointment of Mr Gary Dale Gatchell as an Executive Director to the Board. Gary will also serve as the Company's Finance Director with effect from September 3, 2013.

 

Gary (56) has a demonstrable twenty five year track record of financial experience and expertise. Most recently Gary was Chief Finance Officer of NASDAQ listed Ascent Solar Technologies, Inc. ("Ascent Solar").

 

Gary brings to Iofina a strong background in public company financial reporting and internal controls. He also has experience with private and public capital funding, as well as merger and acquisition activity on both the buy-side and sell-side.

 

From 2005 to 2008, he served as the Chief Financial Officer of Carrier Access Corporation ("Carrier Access"), a telecommunications equipment provider, to reorganise finance and administration infrastructure. Prior to joining Carrier Access, Gary was part of the original founding management team of Voyant Technologies, Inc. ("Voyant"), a leading provider of audio conferencing equipment that was subsequently acquired by Polycom, Inc. Serving as Chief Financial Officer he helped grow Voyant from eight employees to over two hundred, enabling a return of 20x to Voyant's Series A investors, after only four years. A previous audit manager at KPMG, Gary is a registered Certified Public Accountant and has a Master's degree in Accountancy from the University of Denver. 

The Company's current Finance Director, Michael Coddington, will remain with the Company as Chief Financial Officer of Iofina Chemical, Inc., allowing him to focus on the growth and financial aspects of this division. Michael has done an excellent job for the Company during his tenure as Finance Director. As was always planned, once the Company established itself as a key player in the iodine market, strengthening of the Company's financial team was envisioned to ensure rapid growth, good corporate governance and balance the workload across a sound financial management team of which Michael will be a key part.

Commenting on the appointment Dr. Chris Fay, Executive Chairman, said ''We are very pleased to welcome Gary to the Board at a very exciting time in the Company's development. Gary has extensive financial management experience that will be important as Finance Director in order to maximise this exciting rapid time of growth and profitability. The Board would like to thank Michael for his support to date and looks forward to working with him in the future"

 

Save as set out below there is no further information required to be disclosed pursuant to paragraph (g) of Schedule 2 of the AIM Rules:

 

Current Directorships:

Directorships in past 5 years

Colorado Advanced Manufacturing Alliance

 

 

 

For further information, please contact:

 

Dr. Chris Fay, Executive Chairman

Iofina plc

Tel: +44(0)20 3006 3135

www.iofina.com

 

Ben Colegrave/Chris Sim/James Rudd

Investec

Tel: +44(0)20 7597 5970

 

Media Contact:

Dominic Barretto

Yellow Jersey PR Limited

Tel: +44(0) 7768 537 739

 

About Iofina

 

Iofina specializes in the exploration and production of iodine, iodine specialty chemical derivatives, produced water and natural gas. Iofina's business strategy is to identify, develop, build, own and operate iodine extraction plants currently focused in North America based on Iofina's WET® IOsorb™ technology. Iofina has iodine production operations in the United States, specifically in Texas, California, Montana, Oklahoma and Wyoming. The Group has complete vertical integration from the production of iodine in the field to the manufacture of the chemical end products derived from iodine to the consumer and the recycling of iodine using iodinated side-streams from waste chemical processes in Europe, North America and Asia. The Group utilizes its portfolio of patented and patent pending technology, proprietary methods and trademarks throughout all business lines.

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFMGMRKKRGFZM
Date   Source Headline
9th May 20237:00 amRNSNotice of AGM
4th May 20237:00 amRNSInvestor Presentation
28th Apr 20234:45 pmRNSHolding(s) in Company
28th Apr 20237:00 amRNSGrant of Share Options
25th Apr 20237:00 amRNS2022 FULL YEAR RESULTS
12th Apr 20237:00 amRNSProduction Update
20th Feb 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Update
9th Jan 20237:00 amRNSMarket Update
28th Dec 20222:34 pmRNSHolding(s) in Company
14th Dec 20227:00 amRNSIofina Chemical Awarded ISO Certification
21st Nov 20227:00 amRNSChange of Adviser
28th Oct 20227:00 amRNSFinalised Terms for IO9 & Q3 Production Update
26th Sep 202211:06 amRNSSecond Price Monitoring Extn
26th Sep 202211:00 amRNSPrice Monitoring Extension
26th Sep 20227:00 amRNSInterim Results
8th Jul 20227:00 amRNSAdditional Loan Facilities and H1 Update
5th Jul 20228:54 amRNSHolding(s) in Company
22nd Jun 20222:30 pmRNSResult of AGM
20th Jun 20227:00 amRNSAppointment of Chrystal Capital Partners LLP
27th May 20227:00 amRNSNotice of AGM
26th May 20224:15 pmRNSHolding(s) in Company
26th May 20222:15 pmRNSHolding(s) in Company
24th May 20226:15 pmRNSHolding(s) in Company
20th May 20227:10 amRNSInvestor Presentation
18th May 20227:00 amRNSHolding(s) in Company
9th May 20227:00 amRNSFinal Results
5th May 20227:00 amRNSHolding(s) in Company
28th Apr 20228:38 amRNSHolding(s) in Company
19th Apr 20227:00 amRNSQ1 2022 and IO#9 Update
8th Apr 20221:07 pmRNSHolding(s) in Company
17th Mar 20227:00 amRNSDirector/PDMR Shareholding
16th Mar 20227:00 amRNSHolding(s) in Company
14th Mar 20227:00 amRNSDirector/PDMR Shareholding
11th Mar 20227:00 amRNSDirector/PDMR Shareholding
10th Mar 20227:00 amRNSDirector/PDMR Shareholding
9th Mar 20227:00 amRNSGrant of Share Options
8th Mar 20228:51 amRNSHolding(s) in Company
17th Jan 20229:00 amRNSPrice Monitoring Extension
17th Jan 20227:00 amRNSQ4 2021 Update
10th Jan 20227:00 amRNSHolding(s) in Company
10th Jan 20227:00 amRNSHolding(s) in Company
10th Jan 20227:00 amRNSHolding(s) in Company
29th Dec 20217:00 amRNSBusiness Update
20th Oct 202112:44 pmRNSHolding(s) in Company
15th Oct 20217:00 amRNSQ3 2021 Update
12th Oct 20218:47 amRNSHolding(s) in Company
24th Sep 20217:00 amRNSInterim Results
23rd Sep 20214:40 pmRNSSecond Price Monitoring Extn
23rd Sep 20214:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.